NASAL POLYPS TREATMENT MARKET ANALYSIS

Nasal Polyps Treatment Market, By Drug Class (Corticosteroids, Interleukin Inhibitors, Antihistamines, Antibiotics, and Others), By Route of Administration (Nasal, Oral, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On October 14, 2024, GSK plc, a biopharmaceutical company, announced encouraging results from the Phase III ANCHOR trials for depemokimab, a treatment targeting chronic rhinosinusitis with nasal polyps (CRSwNP). Both the ANCHOR-1 and ANCHOR-2 trials successfully met their primary endpoints, showing significant reductions in nasal polyp size and nasal obstruction compared to placebo over a 52-week period. Depemokimab is an ultra-long-acting biologic that can be administered every six months, specifically designed to target interleukin-5 (IL-5), a critical cytokine involved in type 2 inflammation.
On September 13, 2024, Regeneron Pharmaceuticals, Inc., a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).